Outcomes of Surgical Intervention Following Preventive Mastectomy in BRCA1 and BRCA2 Mutation Carriers - Summary - MDSpire

Outcomes of Surgical Intervention Following Preventive Mastectomy in BRCA1 and BRCA2 Mutation Carriers

  • By

  • Rebecca Wiberg

  • Signe Hägglund

  • Barbro Numan Hellquist

  • Anna Rosén

  • Annika Idahl

  • Maria Mani

  • Svetlana Bajalica-Lagercrantz

  • Hans Ehrencrona

  • Per Karlsson

  • Niklas Loman

  • Malin Sund

  • Swedish BRCA Study Group

  • Åke Borg

  • Anna Öfverholm

  • Anna von Wachenfeldt

  • Christina Edwinsdotter Ardnor

  • Ekaterina Kuchinskaya

  • Johanna Rantala

  • Ylva Karlsson

  • April 3, 2026

  • 0 min

Share

Objective:

To analyze surgical outcomes after risk-reducing mastectomy (RRM) in women with germline pathogenic variants (gPVs) in BRCA1/2, focusing on breast cancer incidence, surgical techniques, and postoperative complications.

Key Findings:
  • Bilateral RRM decreases breast cancer incidence by 90% or more, significantly impacting long-term outcomes.
  • Primary breast cancer observed in approximately 1.9% of women after bilateral RRM over 3 to 14 years.
  • Comparable oncologic risks after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) versus simple mastectomy, suggesting safety in aesthetic considerations.
Interpretation:

The study supports the effectiveness of RRM in significantly reducing breast cancer risk in BRCA1/2 mutation carriers, with acceptable oncologic safety for SSM and NSM.

Limitations:
  • Lack of long-term oncologic safety data for SSM and NSM, which may affect clinical decision-making.
  • Potential misclassification of breast cancer types due to historical coding practices, impacting data reliability.
Conclusion:

RRM is a critical intervention for women with BRCA1/2 mutations, significantly lowering breast cancer risk while maintaining acceptable aesthetic outcomes.

Original Source(s)

Outcomes of Surgical Intervention Following Preventive Mastectomy in BRCA1 and BRCA2 Mutation Carriers

  • by Rebecca Wiberg, Signe Hägglund, Barbro Numan Hellquist, Anna Rosén, Annika Idahl, Maria Mani, Svetlana Bajalica-Lagercrantz, Hans Ehrencrona, Per Karlsson, Niklas Loman, Malin Sund, Swedish BRCA Study Group, Åke Borg, Anna Öfverholm, Anna von Wachenfeldt, Christina Edwinsdotter Ardnor, Ekaterina Kuchinskaya, Johanna Rantala, Ylva Karlsson

  • April 3, 2026

Related Content

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 Years

Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer